TS143 / Taisho, BioAge Labs - LARVOL DELTA

COLLECTION AND PRESERVATION OF FIRST-VOID URINARY ANALYTES FOR LIQUID BIOPSY APPLICATIONS (EACR 2023) - "Host cell integrity was inferred using a qPCR assay specific for human DNA (TS143), and microbial growth determined via 16S qPCR...Under simulated ambient temperature transportation conditions, cfDNA (ΔCt: 0.57 ± 1.58), EV RNA (1.05 ± 0.94), and host cell integrity (0.63 ± 0.73) were successfully preserved.ConclusionUrinary cfDNA, EV RNA, and host cell integrity from FVU samples were effectively preserved up to 7 days post-collection at RT, and under simulated ambient temperature transportation. By enabling standardized volumetric FVU collection and analyte preservation, the Colli-Pee® UAS™ FV-5040 device emerges as a non-invasive FVU self-sampling device for oncology applications, simplifying serial and at-home collection."

Biopsy • Liquid biopsy • Oncology • GAPDH

BGE-117 accelerates recovery from eccentric muscle injury and increases voluntary activity Levels (WMS 2022) - "In a separate study, BGE-117 appeared to improve voluntary activity levels of 27+ -month-old mice (p< 0.001 in the AUC comparison): the BGE-117- treated group recorded median daily wheel revolutions of around 5000 vs the vehicle-treated of 2000. The results of these experiments describe a novel skeletal muscle protective effect of PHD inhibition by BGE117, which can be leveraged as a potential therapeutic against muscle dysfunction in older individuals and patients with DMD."

Late-breaking abstract • CNS Disorders • Duchenne Muscular Dystrophy • Genetic Disorders • Muscular Dystrophy • HIF1A

Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging (clinicaltrials.gov) - P2a | N=0 | Withdrawn | Sponsor: BioAge Labs, Inc. | N=160 ➔ 0 | Recruiting ➔ Withdrawn | Trial primary completion date: Nov 2021 ➔ Apr 2022

Enrollment change • Trial primary completion date • Trial withdrawal • Anemia • Hematological Disorders

Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: BioAge Labs, Inc. | N=192 ➔ 0 | Initiation date: Dec 2021 ➔ Apr 2022 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial initiation date • Trial withdrawal • Anemia • Hematological Disorders

Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery (clinicaltrials.gov) - P2; N=192; Not yet recruiting; Sponsor: BioAge Labs, Inc.

Clinical • New P2 trial • Anemia • Hematological Disorders

TP0463518 (TS-143) Ameliorates Peptidoglycan-Polysaccharide Induced Anemia of Inflammation in Rats. (PubMed, Biol Pharm Bull) - "These results suggest that TP0463518 increased iron absorption and improved anemia of inflammation without exacerbating liver inflammation. TP0463518 appears to have an acceptable safety profile and could become a useful new therapeutic option for anemia of inflammation."

Journal • Preclinical • Anemia • Hematological Disorders • Hepatology • Immunology • Inflammation • EPAS1 • EPO

Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Unexplained Anemia of Aging (UAA) (clinicaltrials.gov) - P2a; N=160; Recruiting; Sponsor: BioAge Labs, Inc.

Clinical • New P2a trial • Anemia • Hematological Disorders

Dynamic interactions of Trichoderma harzianum TS 143 from an old mining site in Turkey for potent metal(oid)s phytoextraction and bioenergy crop farming. (PubMed, J Hazard Mater) - "The increase in the carbohydrate content (33%) proves the potential usage of the contaminated maize plants in bioenergy production. Core sustainable agents with their mesh type robust hyphal structure enfolding PTEs such as TS143 contribute to the phytoremediation technology along with potential plant biomass management for the biodiesel industry."

Journal